All In Biotech

Drug Trial Radar · NCT05437263

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 241 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

241

Actual

Start

Oct 31, 2022

Primary completion

Jul 17, 2025

Study completion Sep 9, 2026

Sponsor

Lead sponsor
Priovant Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where all participants will receive brepocitinib.

Conditions

  • Dermatomyositis

Interventions

  • BrepocitinibDrug

    Oral Brepocitinib

  • PlaceboDrug

    Oral Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Improvement Score (TIS) at Week 52Time frame: 52 weeks

Locations

109 sites in 22 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Phoenix, Arizona

  • Clinical Trial Site

    Scottsdale, Arizona

  • Clinical Trial Site

    Scottsdale, Arizona

  • Clinical Trial Site

    Irvine, California

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    San Francisco, California

  • Clinical Trial Site

    Aurora, Colorado

  • Clinical Trial Site

    Denver, Colorado

  • Clinical Trial Site

    Boynton Beach, Florida

  • Clinical Trial Site

    Gainesville, Florida

  • Clinical Trial Site

    Jacksonville, Florida

  • Clinical Trial Site

    Plantation, Florida

  • Clinical Trial Site

    Tampa, Florida

  • Clinical Trial Site

    Atlanta, Georgia

  • Clinical Trial Site

    Augusta, Georgia

  • Clinical Trial Site

    Marietta, Georgia

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Iowa City, Iowa

  • Clinical Trial Site

    Kansas City, Kansas

  • Clinical Trial Site

    New Orleans, Louisiana

  • Clinical Trial Site

    New Orleans, Louisiana

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Ann Arbor, Michigan

  • Clinical Trial Site

    Minneapolis, Minnesota

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    Manhasset, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Cincinnati, Ohio

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Oklahoma City, Oklahoma

  • Clinical Trial Site

    Portland, Oregon

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Pittsburgh, Pennsylvania

  • Clinical Trial Site

    Jackson, Tennessee

  • Clinical Trial Site

    Austin, Texas

  • Clinical Trial Site

    Houston, Texas

  • Clinical Trial Site

    Irving, Texas

  • Clinical Trial Site

    Mendoza, Argentina

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.